Quick Answer
GeneDx Holdings Corp. reported Diluted EPS of $0.73 per share (loss) for fiscal year 2025.
GeneDx Holdings Corp. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.73 | +62.4% |
| 2024 | -$1.94 | +73.2% |
| 2023 | -$7.23 | +86.5% |
| 2022 | -$53.63 | -2262.6% |
| 2021 | -$2.27 | +100.0% |
| 2020 | -$47036.00 | +82.2% |
| 2019 | -$264056.00 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.27 | +12.9% | -175.0% |
| June 30, 2025 | $0.36 | +132.7% | +256.5% |
| March 31, 2025 | -$0.23 | +70.5% | +25.8% |
| September 30, 2024 | -$0.31 | +81.1% | +71.8% |
| June 30, 2024 | -$1.10 | +40.2% | -41.0% |
| March 31, 2024 | -$0.78 | +74.3% | +52.4% |
| September 30, 2023 | -$1.64 | +75.6% | +10.9% |
| June 30, 2023 | -$1.84 | +78.0% | +39.5% |
- GeneDx Holdings Corp. showed an increase of +62.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, GeneDx Holdings Corp.’s diluted eps has grown by 100.0% (from $264056.00 per share (loss) to $0.73 per share (loss)).
- The most recent figure is from GeneDx Holdings Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: